Heparin - Pharmacology
Research News and Information

Monday, November 23, 2009

Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment.

29 Nov 2009 Heparin (HP) inhibits pulmonary artery smooth muscle cell (PASMC) growth in vitro and vascular remodeling in vivo. Bârzu et al. (1994) suggested that the antiproliferative effect of HP on rat aortic smooth muscle cell in vitro diminishes with ... Read more...

Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo.

30 Oct 2009 The adhesion of tumor cells with platelets is important in the process of tumor metastasis. A huge work has indicated that anti-adhesion is an effective strategy for metastasis inhibition. In this article, we assess the role of platelet integrin ... Read more...

Leukemia inhibitory factor favours neurogenic differentiation of long-term propagated human midbrain precursor cells.

20 Aug 2009 There is a lot of excitement about the potential use of multipotent neural stem cells for the treatment of neurodegenerative diseases. However, the strategy is compromised by the general loss of multipotency and ability to generate neurons after ... Read more...

Latest indexed articles for 'Heparin - Pharmacology'

These are the very latest articles for this heading:

• Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment. 29 Nov 2009
• Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo. 30 Oct 2009
• Leukemia inhibitory factor favours neurogenic differentiation of long-term propagated human midbrain precursor cells. 20 Aug 2009
• Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. 3 Aug 2009
• Rapid blood separation is superior to fluoride for preventing in vitro reductions in measured blood glucose concentration. 30 Jul 2009
• Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. 30 Jul 2009
• Evaluation of six portable blood glucose meters for measuring blood glucose concentration in dogs. 30 Jul 2009
• Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding. 30 Jul 2009
• Critical role of heparin binding domains of ameloblastin for dental epithelium cell adhesion and ameloblastoma proliferation. 29 Jul 2009
• High negative charge-to-size ratio in polyphosphates and heparin regulates factor VII-activating protease. 29 Jul 2009
• In vivo recruitment of hematopoietic cells using stromal cell-derived factor 1 alpha-loaded heparinized three-dimensional collagen scaffolds. 29 Jun 2009
• Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature. 28 Jun 2009
• MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity. 27 Jun 2009
• Sulfonation and anticoagulant activity of botryosphaeran from Botryosphaeria rhodina MAMB-05 grown on fructose. 19 Jun 2009
• Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. 14 Jun 2009
• The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells. 13 Jun 2009
• Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C-terminal peptides eliminate serum-resistant Escherichia coli from blood cultures. 13 Jun 2009
• Controlled release of glial-derived neurotrophic factor from fibrin matrices containing an affinity-based delivery system. 13 Jun 2009
• Hirudin versus heparin for use in whole blood in vitro biocompatibility models. 13 Jun 2009
• Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. 13 Jun 2009

See a longer list of these articles.

Technical information about 'Heparin'

Definition: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

Registry Number: 9005-49-6

Descriptor UI: D006493

Alternative terms: Heparin; Heparinic Acid; Liquaemin; Sodium Heparin; Heparin, Sodium; Heparin Sodium; alpha-Heparin; alpha Heparin;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; ultrastructure;

Pharmacological Action: Fibrinolytic Agents; Anticoagulants;

Tree Number: D09.698.373.400;

History Note: /therapeutic use was HEPARIN, THERAPEUTIC 1965